A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2016
At a glance
- Drugs C 82 (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors PRISM Pharma Co
- 07 Jun 2017 Biomarkers information updated
- 26 Sep 2016 Status changed from active, no longer recruiting to completed.
- 31 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jun 2016.